Disclosed is an orally-administered pharmaceutical composition or kit for eradicating Helicobacter pylori comprising a complex of a non-absorbable antibiotic and a clay mineral. The pharmaceutical composition or kit of the present disclosure may further comprise a β-lactam antibiotic and/or a gastric acid-suppressive agent.

The invention in suitable embodiments is directed to dynamic bio-nanoparticle elements and bio-nanoparticle platforms employing such bio-nanoparticle elements. In one aspect, one or more elements of one or more types, formed from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more types of Clathrin and or Coatomer I/II proteins of one or more isoforms, execute one or more functions and or effect one or more ends, in vivo and or in vitro.

Formulations are described, containing silibinin or other active ingredients incorporated in lipid nanoparticle systems of the SLN and NLC type, and based on calixarenes, possibly mucoadhesive, or in micellar and nanoparticle systems based on amphiphilic inulin copolymers for use in the treatment of neurodegenerative ocular diseases. The versatility of the calixarene compound is also described, capable of charging and releasing active ingredients characterized by low water solubility, easy chemical and enzymatic degradation, low bioavailability, either of natural origin or not, to be used in the treatment of ocular diseases.

An antimicrobial composition of buckminsterfullerene with saponified phosphorus acid functional groups is provided to disassemble or make virus particles inert, and to inhibit viral and fungal proteases using catalytic desulfurization. This composition is formulated to prevent or to treat novel corona viruses including emerging strains of SARS-Cov-2, as well as fungal pathologies such as valley fever and respiratory ailments such as chronic obstructive pulmonary disorder (COPD) and pneumonia. Virus particles are implicated in the development of cancers. The antiviral properties further enable the composition to prevent conditions leading to uncontrolled cellular proliferation, neoplasms, degenerative malignancy, and to help treat chronic inflammatory diseases associated with or leading to induce cancer in virus infected cells. The composition can be produced at low temperatures through reactive shear mixing. Delivery methods include ingestion, topical application, inhalation, or injection when used as a medicament or as a food supplement.

A nanoparticle composition of buckminsterfullerene with ellagic acid is provided that becomes substantially more efficacious to maintain or re-establish benign healthy cellular homeostasis with the functionalization of at least about 10% luteolin. This composition is formulated to prevent or to treat chronic obstructive pulmonary disorder (COPD). In addition, the ability to penetrate hydrophobic malignant tissues via desulfurization is promoted with the addition of phosphonate pendant groups. This further enables the composition to penetrate fungal spores, the hydrophobic regions of uncontrolled cellular proliferation, neoplasms, degenerative malignancy, and to help treat chronic inflammatory diseases associated with or leading to induce cancer in susceptible cells. The composition can be produced at low temperatures through reactive shear milling. Delivery methods include ingestion, topical application, topical buccal application, inhalation, or injection when used as a medicament or as a food supplement.

A drug delivery system delivers a cyclic compound to a target cell or tissue while suppressing the pharmacological activity of the cyclic compound. A complex includes the cyclic compound and a delivery carrier having a shaft portion for carrying the cyclic compound. The shaft portion is complexed by inclusion in the cyclic compound to form a host-guest complex.

A dual neurotransmitter nanoparticle composition is provided to store and transport protons and cations across neural cell membranes. This composition mitigates cognitive deficits in neurological pathologies such as autism spectrum disorder and some symptoms of Alzheimer's disease, as well as to reduce the severity of aging related reactive oxygen species damage in ASD and AD brains that are caused by bioenergetic dysfunction. The antioxidant and protein oligomer disassembly properties can also be used to alleviate corneal cataracts. The composition comprises C60 fullerenes bonded to one glutathione molecule and one or more molecules of adenosine triphosphate and can be produced at low temperatures through reactive shear mixing. This composition therapeutically improves and prophylactically preserves cognitive performance, memory, and mental acuity to alleviate deficits arising from bio-electrochemical dysfunction in brain cells.

A composition includes a photon upconversion nanoparticle coupled to a photosensitizer nanoparticle that can absorb light and convert tissue oxygen into reactive oxygen species. A low temperature hydrothermal method of making photon upconversion nanoparticles includes dispersing Yb(NO.sub.3).sub.3, Y(NO.sub.3).sub.3, and Er(NO.sub.3).sub.3 in water to prepare a mixture; adding an ethylenediaminetetraacetic acid and NaF with sonication to make a solution; adjusting a pH of the solution to approximately 3.5 using HNO.sub.3 and NaOH; treating the solution hydrothermally at approximately 130° C. for approximately 4 hours; quenching to approximately 20° C.; collecting and washing the photon upconversion nanoparticles. A near infrared triggered photon upconversion method for synergistic photodynamic and photothermal cancer therapy includes administering a nanocomposite comprising a photon upconversion nanoparticle coupled to a photosensitizer nanoparticle that can absorb light and convert tissue oxygen into reactive oxygen species; and exposing the mammal and the nanocomposite to a near infrared source of actinic radiation.

A biodegradable microneedle (MN) patch is disclosed for transdermal gene delivery. The MN patch, in one embodiment, is a gelatin methacryloyl (GelMA)-based MN platform for the local and controlled transdermal delivery of plasmid DNA (pDNA) (or other nucleic acid with high transfection efficiency both in vitro and in vivo. Intracellular delivery of the nucleic acid cargo is enabled by poly(β-amino ester) (PBAE). After being embedded in the GelMA MNs, sustained release of DNA-encapsulated PBAE nanoparticles (NPs) is achieved and the release profiles can be controlled by adjusting the degree of crosslinking of the GelMA. These results highlight the advantages and potential of using PBAE/DNA NPs embedded GelMA MN patches (MN/PBAE/DNA) for successful transdermal delivery of pDNA for tissue regeneration, cancer therapy, and other applications. The patch may also be used on other tissue types.

Embodiments of the present disclosure relate to materials and methods for preparing a clathrate-forming composition comprising a plurality of linear glucomonomer chains of about 15 to about 100 D-glucopyranosyl residues linked by α-1,4 linkages, wherein the linear glucomonomer chains are a product of partial amylolysis of a modified starch substrate and wherein the product is flowable at temperatures within a range of 4-20° C. at about 20% w/v solids content. The present disclosure further describes methods of using the clathrate-forming compositions to form molecular dispersions or clathrates with hydrophobic guest molecules, kits for use in these methods, and molecular dispersions or clathrates obtained from the materials.